A Phase II Exploratory Study of Sacituzumab Tirumotecan Combined With Envafolimab for TROP2-Positive Advanced Biliary Tract Cancers Previously Treated With First-Line Immunotherapy Combined With Chemotherapy.

NCT07729033 · clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
28
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Tianjin Medical University Cancer Institute and Hospital